Anti Reflux surgery
LINX device
Magnetic Sphincter Augmentation Device
This is a controlled document. If you are using a printed copy, check it against the guidelines site to ensure you are using the latest edition.
Print copies must be destroyed after use.
Abbreviations
| BMI | Body Mass Index |
|---|---|
| DCI | Distal Contractile Integral |
| GOJ | Gastro-oesophageal Junction |
| MDT | Multi disciplinary meeting |
| MSAD | Magnetic Sphincter augmentation device |
No or small hiatal hernia.
No revisions.
Pathological reflux on pH studies.
DCI on solid swallows >450mmHg.cm.s and normal manometry.
No dysphagia.
BMI <35.
No Barrett’s.
Licensed for reflux treatment in patients post sleeve gastrectomy.
Discussion at MDT for all LINX cases is required, it is encouraged for all hiatal cases.
Data about case and outcomes to be added to the FHFT LINX dataset in the shared drive by the surgeon. Once the NHSR is back up and running all cases will be added to NHSR.
As dysphagia peaks at 6 weeks and subsides by week 12, follow up will be by phone week 1 then face to face at 12 weeks post operatively.
Allergies to titanium, stainless steel, nickel or ferrous materials.
Johnson and Johnson Med Tech (2023) LINX Reflux Management System. Available at: https://www.jnjmedtech.com/en-GB/product/linx-reflux-management-system (Accessed: 04 April 2025).
SAGES (2017) LINX® Reflux Management System. Available at: https://www.sages.org/publications/tavac/tavac-safety-and-effectiveness-analysis-linx-reflux-management-system/ (Accessed: 04 April 2025).
National Institute for Health and Care Excellence [NICE] (2023) Laparoscopic insertion of a magnetic ring for gastro-oesophageal reflux disease. IPG749. Available at: https://www.nice.org.uk/guidance/ipg749 (Accessed: 04 April 2025).
| Version: | 1.0 |
|---|---|
| Guidelines Lead(s): | Jihene El Kafsi, Consultant UGI Surgeon |
| Contributor(s): | |
| Lead Director / Chief of Service: | David Gerrard, CoS for Surgical Services |
| Library check completed: | 26/2/25 |
| Ratified at: | Cross site UGI Surgery Clinical Governance meeting 19 February 2025 |
| Date Issued: | 7 April 2025 |
| Review Date: | February 2028 |
| Pharmaceutical dosing advice and formulary compliance checked by: | N/A |
| Key words: | anti-reflux surgery, LINX, Magnetic Sphincter Augmentation device |
This guideline has been registered with the Trust. However, clinical guidelines are guidelines only. The interpretation and application of clinical guidelines will remain the responsibility of the individual clinician. If in doubt, contact a senior colleague or expert. Caution is advised when using guidelines after the review date.
This guideline is for use in Frimley Health NHS Foundation Trust hospitals only. Any use outside this location will not be supported by the Trust and will be at the risk of the individual using it.
Version History
| Version | Date | Guideline Lead(s) | Status | Comment |
|---|---|---|---|---|
| 1 | April 2025 | Jihene El Kafsi | Final |
Related Documents
| Document Type | Document Name |
|---|---|
| Guideline | Laparoscopic Anti-Reflux Surgery |